Liquidia – $53 Million IPO

Washington, DC – August 21, 2018 – Cooley advised the underwriters on Liquidia Technologies’ $53.2 million initial public offering of 4,833,099 shares of common stock, which included 287,644 shares issued upon the underwriters’ partial exercise of their option to purchase additional shares to cover over-allotments. Partners Brent Siler, Brian Leaf and Div Gupta led the Cooley team advising the underwriters. 

Jefferies and Cowen acted as the lead book-running managers for the offering. Needham & Company and Wedbush PacGrow acted as co-managers for the offering.

Liquidia Technologies, which now trades on the Nasdaq Capital Market as “LQDA,” is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients.

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.